Zhang Dandan, Zhang Junyu, Chen Simian, Zhang Hairong, Yang Yuexin, Jiang Shan, Hong Yun, Zhu Mingshe, Xie Qiang, Wu Caisheng
Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cell Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, Fujian, China.
Mass Defect Technologies, Princeton, NJ, USA.
Chin Med. 2024 Nov 14;19(1):158. doi: 10.1186/s13020-024-01031-8.
Deciphering the in vivo processes of traditional Chinese medicine (TCM) is crucial for identifying new pharmacodynamic substances and new drugs. Due to the complexity and diversity of components, investigating the exposure, metabolism, and disposition remains a major challenge in TCM research. In recent years, a number of non-targeted smart mass-spectrometry (MS) techniques, such as precise-and-thorough background-subtraction (PATBS) and metabolomics, have realized the intelligent identification of in vivo components of TCM. However, the metabolites characterization still largely relies on manual identification in combination with online databases.
We developed a scoring approach based on the structural similarity and minimal mass defect variations between metabolites and prototypes. The current method integrates three dimensions of mass spectral data including m/z, mass defect of MS1 and MS2, and the similarity of MS2 fragments, which was sequentially analyzed by a R-based mass dataset relevance bridging (MDRB) data post-processing technique. The MDRB technology constructed a component relationship network for TCM, significantly improving metabolite identification efficiency and facilitating the mapping of translational metabolic pathways. By combining MDRB with PATBS through this non-targeted identification technology, we developed a comprehensive strategy for identification, characterization and bridging analysis of TCM metabolite in vivo. As a proof of concept, we adopted the proposed strategy to investigate the process of exposure, metabolism, and disposition of Semen Armeniacae Amarum (CKXR) in mice.
The currently proposed analytical approach is universally applicable and demonstrates its effectiveness in analyzing complex components of TCMs in vitro and in vivo. Furthermore, it enables the correlation of in vitro and in vivo data, providing insights into the metabolic transformations among components sharing the same parent nucleus structure. Finally, the developed MDRB platform is publicly available for ( https://github.com/933ZhangDD/MDRB ) for accelerating TCM research for the scientific community.
阐明中药的体内过程对于鉴定新的药效物质和新药至关重要。由于成分的复杂性和多样性,研究中药的暴露、代谢和处置仍然是中药研究中的一项重大挑战。近年来,一些非靶向智能质谱(MS)技术,如精确彻底背景扣除(PATBS)和代谢组学,已经实现了对中药体内成分的智能鉴定。然而,代谢物表征在很大程度上仍依赖于结合在线数据库的人工鉴定。
我们开发了一种基于代谢物与原型之间结构相似性和最小质量缺陷变化的评分方法。当前方法整合了质谱数据的三个维度,包括质荷比、MS1和MS2的质量缺陷以及MS2碎片的相似性,通过基于R的质量数据集相关性桥接(MDRB)数据后处理技术进行顺序分析。MDRB技术构建了中药的成分关系网络,显著提高了代谢物鉴定效率,并促进了转化代谢途径的映射。通过这种非靶向鉴定技术将MDRB与PATBS相结合,我们开发了一种用于体内中药代谢物鉴定、表征和桥接分析的综合策略。作为概念验证,我们采用所提出的策略研究了苦杏仁(CKXR)在小鼠体内的暴露、代谢和处置过程。
目前提出的分析方法具有普遍适用性,并在体外和体内分析中药复杂成分方面证明了其有效性。此外,它能够关联体外和体内数据,深入了解具有相同母核结构的成分之间的代谢转化。最后,开发的MDRB平台可公开获取(https://github.com/933ZhangDD/MDRB),以加速科学界的中药研究。